Bausch Health Companies Inc. sits at the most consequential inflection point in its post-Valeant history. The Laval, Quebec-headquartered specialty pharmaceutical company is no longer the sprawling, debt-laden conglomerate that emerged from the 2015-2017 pharmaceutical pricing controversy under its former name. It is now a deliberately shrinking, three-segment specialty pharma anchored by a dominant gastroenterology franchise and a globally significant eyecare business that management and the board have publicly committed to separating from the parent. The investment debate in 2026 is not whether Bausch + Lomb will eventually become a standalone public company, but rather the pace, structure, and tax efficiency of the separation, and the deleveraging trajectory of the remaining Bausch Health shell in the interim.
The four-segment structure that defined Bausch Health for most of the post-2018 rebranding period has narrowed meaningfully. The Solta medical aesthetics business, which houses the Thermage, Fraxel, and Clear + Brilliant device franchises, was spun off in late 2024 into a standalone publicly traded entity, removing a non-core capital-intensive device business from the parent's balance sheet and leaving Bausch Health with three reportable segments: Bausch + Lomb (eyecare), Salix (gastroenterology), and Diversified Products (dermatology, generics, and a long tail of mature brands). The strategic logic of that 2024 transaction was to simplify the parent, sharpen the investor narrative around the two crown-jewel franchises, and accelerate the path to a Bausch + Lomb separation. Two years on, the simplification has been achieved. The remaining question is execution.
The Salix segment, built around the Xifaxan (rifaximin) franchise for hepatic encephalopathy, irritable bowel syndrome with diarrhea, and small intestinal bacterial overgrowth, remains the most strategically valuable asset inside the parent. Xifaxan is a durable, high-margin, patent-protected cash cow with limited generic threat through the latter half of the decade, and the broader Salix portfolio of gastroenterology products generates a disproportionate share of the parent's profitability. The segment functions as the cash engine funding the parent's deleveraging plan and underwriting the cost of eventually distributing Bausch + Lomb equity to BHC shareholders.
The Bausch + Lomb separation, whether structured as a tax-free spin-off, a Reverse Morris Trust transaction, or a more conventional separation with a partial debt assumption, is the single most important catalyst in the BHC equity story. Bausch + Lomb is the largest eyecare company in the world by revenue, with a portfolio spanning contact lenses (Biotrue, Ultra), intraocular lenses used in cataract surgery, ophthalmic pharmaceuticals (including the Lotemax and Besivance franchises), and consumer vision care. As a standalone public company, Bausch + Lomb would trade at a meaningfully higher multiple than the embedded valuation inside Bausch Health, where the parent trades at a conglomerate discount driven by the legacy debt load and the Salix franchise's patent-cliff overhang. The arbitrage between the current BHC equity value and the sum-of-the-parts value is the central opportunity.
Bausch Health's debt situation is the second pillar of the story. The company inherited roughly $30 billion of debt at the Valeant peak and has spent the better part of a decade working it down through asset sales, free cash flow allocation, and equity-funded refinancing. Net debt is now in the $13-15 billion range, and the company has executed a series of liability management transactions over the past several years, including exchange offers and tender transactions, to extend maturities and reduce near-term refinancing risk. Deleveraging continues to consume a disproportionate share of operating cash flow, constraining the parent's ability to invest in growth, return capital to shareholders, or pursue transformative M&A. The separation of Bausch + Lomb, with new debt sitting at the spun entity rather than the parent, would meaningfully accelerate Bausch Health's deleveraging and potentially unlock investment-grade credit metrics for the residual business on a multi-year horizon.
The litigation overhang is a real but increasingly well-bounded risk. Bausch Health faces a Securities Act class action stemming from disclosures made during the Valeant era, antitrust settlements related to legacy generics pricing conduct, and a tail of product liability and regulatory exposures. The Securities Act class action has progressed through discovery and is approaching trial or settlement in the 2026-2027 window. Antitrust settlements have been resolved through cash payments in some cases and are accruing in others. The total litigation reserve, while not trivial, is not large enough to derail the separation or the deleveraging plan, but it does represent a non-zero probability of episodic cash outflows that can interrupt the parent's deleveraging cadence.
The investment case is therefore a story about a multi-year separation catalyst, a deleveraging trajectory that bends the credit curve toward investment grade, and a sum-of-the-parts valuation arbitrage. The bear case is a slower-than-expected separation, an unfavorable tax structure, a Salix patent-cliff that arrives earlier or more steeply than expected, or a credit event driven by an operating disappointment or an outsized legal settlement. The base case is a 2027 separation, a 2027-2028 debt step-down at the parent, and a re-rating of the BHC equity as the separation nears. The bull case is a 2026 separation announcement, a meaningful partial paydown of parent debt funded by separation proceeds, and a re-rating of both the parent and the spin as standalone entities.
BHC equity at the current level prices in much of the bear case and only a fraction of the bull case. The asymmetry of the setup, a 2027 separation catalyst with embedded optionality on the structure, the timing, and the parent deleveraging, is what makes the name worth a deep look heading into the back half of 2026.